1-10 of 10
Nayyar Iqbal
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Microvascular and Cardiovascular Outcomes According to Renal Function in Patients Treated With Once-Weekly Exenatide: Insights From the EXSCEL Trial

M. Angelyn Bethel, Robert J. Mentz, Peter Merrill, John B. Buse, Juliana C. Chan, Shaun G. Goodman, Nayyar Iqbal, Neli Jakuboniene, Brian Katona, Yuliya Lokhnygina, Renato D. Lopes, Aldo P. Maggioni, Peter Ohman, Tsvetalina Tankova, George L. Bakris, Adrian F. Hernandez, Rury R. Holman
Journal: Diabetes Care
Diabetes Care 2020;43(2):446–452
https://doi.org/10.2337/dc19-1065
Published: 22 November 2019
View article titled, Microvascular and Cardiovascular Outcomes According to Renal Function in Patients Treated With Once-Weekly Exenatide: Insights From the EXSCEL Trial
Open the PDF for Microvascular and Cardiovascular Outcomes According to Renal Function in Patients Treated With Once-Weekly Exenatide: Insights From the EXSCEL Trial in another window
Includes: Supplementary data
Journal Articles

Changes in Serum Calcitonin Concentrations, Incidence of Medullary Thyroid Carcinoma, and Impact of Routine Calcitonin Concentration Monitoring in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL)

M. Angelyn Bethel, Rishi A. Patel, Vivian P. Thompson, Peter Merrill, Shelby D. Reed, Yanhong Li, Sara Ahmadi, Brian G. Katona, Stephanie M. Gustavson, Peter Ohman, Nayyar Iqbal, Robert F. Gagel, Adrian F. Hernandez, John B. Buse, Rury R. Holman
Journal: Diabetes Care
Diabetes Care 2019;42(6):1075–1080
https://doi.org/10.2337/dc18-2028
Published: 22 April 2019
View article titled, Changes in Serum Calcitonin Concentrations, Incidence of Medullary Thyroid Carcinoma, and Impact of Routine Calcitonin Concentration Monitoring in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL)
Open the PDF for Changes in Serum Calcitonin Concentrations, Incidence of Medullary Thyroid Carcinoma, and Impact of Routine Calcitonin Concentration Monitoring in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) in another window
Includes: Supplementary data
Journal Articles

Effect of Saxagliptin on Renal Outcomes in the SAVOR-TIMI 53 Trial

Ofri Mosenzon, Gil Leibowitz, Deepak L. Bhatt, Avivit Cahn, Boaz Hirshberg, Cheryl Wei, KyungAh Im, Aliza Rozenberg, Ilan Yanuv, Christina Stahre, Kausik K. Ray, Nayyar Iqbal, Eugene Braunwald, Benjamin M. Scirica, Itamar Raz
Journal: Diabetes Care
Diabetes Care 2017;40(1):69–76
https://doi.org/10.2337/dc16-0621
Published: 17 October 2016
View article titled, Effect of Saxagliptin on Renal Outcomes in the SAVOR-TIMI 53 Trial
Open the PDF for Effect of Saxagliptin on Renal Outcomes in the SAVOR-TIMI 53 Trial in another window
Includes: Supplementary data
Journal Articles

Predisposing Factors for Any and Major Hypoglycemia With Saxagliptin Versus Placebo and Overall: Analysis From the SAVOR-TIMI 53 Trial

Avivit Cahn, Itamar Raz, Ofri Mosenzon, Gil Leibowitz, Ilan Yanuv, Aliza Rozenberg, Nayyar Iqbal, Boaz Hirshberg, Mikaela Sjostrand, Christina Stahre, KyungAh Im, Estella Kanevsky, Benjamin M. Scirica, Deepak L. Bhatt, Eugene Braunwald
Journal: Diabetes Care
Diabetes Care 2016;39(8):1329–1337
https://doi.org/10.2337/dc15-2763
Published: 23 May 2016
View article titled, Predisposing Factors for Any and Major Hypoglycemia With Saxagliptin Versus Placebo and Overall: Analysis From the SAVOR-TIMI 53 Trial
Open the PDF for Predisposing Factors for Any and Major Hypoglycemia With Saxagliptin Versus Placebo and Overall: Analysis From the SAVOR-TIMI 53 Trial in another window
Includes: Supplementary data
Journal Articles

Randomized, Double-Blind Trial of Triple Therapy With Saxagliptin Add-on to Dapagliflozin Plus Metformin in Patients With Type 2 Diabetes

Stephan Matthaei, Doina Catrinoiu, Aleksander Celiński, Ella Ekholm, William Cook, Boaz Hirshberg, Hungta Chen, Nayyar Iqbal, Lars Hansen
Journal: Diabetes Care
Diabetes Care 2015;38(11):2018–2024
https://doi.org/10.2337/dc15-0811
Published: 31 August 2015
View article titled, Randomized, Double-Blind Trial of Triple Therapy With Saxagliptin Add-on to Dapagliflozin Plus Metformin in Patients With Type 2 Diabetes
Open the PDF for Randomized, Double-Blind Trial of Triple Therapy With Saxagliptin Add-on to Dapagliflozin Plus Metformin in Patients With Type 2 Diabetes in another window
Includes: Supplementary data
Journal Articles

Randomized, Double-Blind, Phase 3 Trial of Triple Therapy With Dapagliflozin Add-on to Saxagliptin Plus Metformin in Type 2 Diabetes

Chantal Mathieu, Aurelian Emil Ranetti, Danshi Li, Ella Ekholm, William Cook, Boaz Hirshberg, Hungta Chen, Lars Hansen, Nayyar Iqbal
Journal: Diabetes Care
Diabetes Care 2015;38(11):2009–2017
https://doi.org/10.2337/dc15-0779
Published: 05 August 2015
View article titled, Randomized, Double-Blind, Phase 3 Trial of Triple Therapy With Dapagliflozin Add-on to Saxagliptin Plus Metformin in Type 2 Diabetes
Open the PDF for Randomized, Double-Blind, Phase 3 Trial of Triple Therapy With Dapagliflozin Add-on to Saxagliptin Plus Metformin in Type 2 Diabetes in another window
Includes: Supplementary data
Journal Articles

Dual Add-on Therapy in Type 2 Diabetes Poorly Controlled With Metformin Monotherapy: A Randomized Double-Blind Trial of Saxagliptin Plus Dapagliflozin Addition Versus Single Addition of Saxagliptin or Dapagliflozin to Metformin

Julio Rosenstock, Lars Hansen, Pamela Zee, Yan Li, William Cook, Boaz Hirshberg, Nayyar Iqbal
Journal: Diabetes Care
Diabetes Care 2015;38(3):376–383
https://doi.org/10.2337/dc14-1142
Published: 28 October 2014
View article titled, Dual Add-on Therapy in Type 2 Diabetes Poorly Controlled With Metformin Monotherapy: A Randomized Double-Blind Trial of Saxagliptin Plus Dapagliflozin Addition Versus Single Addition of Saxagliptin or Dapagliflozin to Metformin
Open the PDF for Dual Add-on Therapy in Type 2 Diabetes Poorly Controlled With Metformin Monotherapy: A Randomized Double-Blind Trial of Saxagliptin Plus Dapagliflozin Addition Versus Single Addition of Saxagliptin or Dapagliflozin to Metformin in another window
Includes: Supplementary data
Journal Articles

Exploring the Potential of the SGLT2 Inhibitor Dapagliflozin in Type 1 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Pilot Study

Robert R. Henry, Julio Rosenstock, Steven Edelman, Sunder Mudaliar, Alexandros-Georgios Chalamandaris, Sreeneeranj Kasichayanula, Allyson Bogle, Nayyar Iqbal, James List, Steven C. Griffen
Journal: Diabetes Care
Diabetes Care 2015;38(3):412–419
https://doi.org/10.2337/dc13-2955
Published: 30 September 2014
View article titled, Exploring the Potential of the SGLT2 Inhibitor Dapagliflozin in Type 1 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Pilot Study
Open the PDF for Exploring the Potential of the SGLT2 Inhibitor Dapagliflozin in Type 1 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Pilot Study in another window
Includes: Supplementary data
Journal Articles

Incidence of Pancreatitis and Pancreatic Cancer in a Randomized Controlled Multicenter Trial (SAVOR-TIMI 53) of the Dipeptidyl Peptidase-4 Inhibitor Saxagliptin

Itamar Raz, Deepak L. Bhatt, Boaz Hirshberg, Ofri Mosenzon, Benjamin M. Scirica, Amarachi Umez-Eronini, KyungAh Im, Christina Stahre, Alona Buskila, Nayyar Iqbal, Norton Greenberger, Markus M. Lerch
Journal: Diabetes Care
Diabetes Care 2014;37(9):2435–2441
https://doi.org/10.2337/dc13-2546
Published: 07 August 2014
View article titled, Incidence of Pancreatitis and Pancreatic Cancer in a Randomized Controlled Multicenter Trial (SAVOR-TIMI 53) of the Dipeptidyl Peptidase-4 Inhibitor Saxagliptin
Open the PDF for Incidence of Pancreatitis and Pancreatic Cancer in a Randomized Controlled Multicenter Trial (SAVOR-TIMI 53) of the Dipeptidyl Peptidase-4 Inhibitor Saxagliptin in another window
Includes: Supplementary data
Journal Articles

Association of Lower Plasma Fetuin-A Levels With Peripheral Arterial Disease in Type 2 Diabetes

Luis H. Eraso, MD, Naeema Ginwala, BA, Atif N. Qasim, MD, Nehal N. Mehta, MD, Rachel Dlugash, BA, Shiv Kapoor, PHD, Stanley Schwartz, MD, Mark Schutta, MD, Nayyar Iqbal, MD, Emile R. Mohler, III, MD, Muredach P. Reilly, MB
Journal: Diabetes Care
Diabetes Care 2010;33(2):408–410
https://doi.org/10.2337/dc09-1541
Published: 12 November 2009
View article titled, Association of Lower Plasma Fetuin-A Levels With Peripheral Arterial Disease in Type 2 Diabetes
Open the PDF for Association of Lower Plasma Fetuin-A Levels With Peripheral Arterial Disease in Type 2 Diabetes in another window
Includes: Supplementary data